Cargando…

Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse

BACKGROUND: Antithyroid drug (ATD) treatment occupies the cornerstone therapeutic modality of Graves' disease (GD) with a high relapse rate after discontinuation. This study aimed to assess potential risk factors for GD relapse especially serum interleukin-17 (IL-17) expression. METHODS: Consec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jianhui, Sun, Xiaohua, Yao, Danzhen, Xia, Jinying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866853/ https://www.ncbi.nlm.nih.gov/pubmed/29713343 http://dx.doi.org/10.1155/2018/5689030

Ejemplares similares

Development of a Nomogram for Estimating the Risk of Left Ventricular Diastolic Dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
por: Xia, Jinying, et al.
Publicado: (2022)

Decreased serum levels of IL-27and IL-35 in patients with Graves disease
por: Saeed, Malek-Hosseini, et al.
Publicado: (2020)

Identification of lncRNA and mRNA Expression Profile in Relapsed Graves’ Disease
por: Yao, Qiuming, et al.
Publicado: (2021)

IL-17A and Serum Amyloid A Are Elevated in a Cigarette Smoke Cessation Model Associated with the Persistence of Pigmented Macrophages, Neutrophils and Activated NK Cells
por: Hansen, Michelle J., et al.
Publicado: (2014)

Elevated Interleukin-36α And CD4(+)IL-36α(+)T Cells Are Involved in the Pathogenesis of Graves' Disease
por: Yao, Qiu-ming, et al.
Publicado: (2018)

Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012)

Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α
por: Jin, Xian-Hua, et al.
Publicado: (2019)

Serum IL-17A in Behçet's disease
por: Emiroglu, Nazan, et al.
Publicado: (2015)

Elevated Expression and Activation of GPR15 in Immune Cells in Graves’ Disease
por: Zhao, Jing, et al.
Publicado: (2022)

Serum Levels of CXCL-13, RBP-4, and IL-6, and Correlation Analysis of Patients with Graves' Disease
por: Hu, Yanqin, et al.
Publicado: (2022)

Graves’ Ophthalmopathy Misdiagnosed as Relapsing Conjunctivitis
por: Chatziralli, Irini P., et al.
Publicado: (2010)

Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis
por: Robak, Ewa, et al.
Publicado: (2019)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Elevated Levels of Serum IL-17A in Community-Dwelling Women with Higher Depressive Symptoms
por: Tsuboi, Hirohito, et al.
Publicado: (2018)

Metabolomics for Prediction of Relapse in Graves' Disease: Observational Pilot Study
por: Struja, Tristan, et al.
Publicado: (2018)

Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Elevated Serum Levels of IL-21 in Kawasaki Disease
por: Bae, Yon Jung, et al.
Publicado: (2012)

Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
por: Da Silva Santos, Tiago, et al.
Publicado: (2022)

Relapse of Graves' disease in Chinese children: a retrospective cohort study
por: Cui, Yiyun, et al.
Publicado: (2023)

Erratum to: Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
Publicado: (2021)

Attenuation of relapsing fever neuroborreliosis in mice by IL-17A blockade
por: Cheng, Meihui, et al.
Publicado: (2022)

NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay
por: Giusti, Delphine, et al.
Publicado: (2019)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

The Expression of Notch/Notch Ligand, IL-35, IL-17, and Th17/Treg in Preeclampsia
por: Cao, Weiping, et al.
Publicado: (2015)

Enhancement of soluble CD28 levels in the serum of Graves’ disease
por: Sun, Zhongwen, et al.
Publicado: (2014)

Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves’ Disease
por: Zhao, J., et al.
Publicado: (2018)

IL-17 and IL-22 in Cerebrospinal Fluid and Plasma Are Elevated in Guillain-Barré Syndrome
por: Li, Shujuan, et al.
Publicado: (2012)

SAT469 Risk Factors for Relapse in Graves’ Disease and the Clinical Outcomes of Radioactive Iodine Treatment in Relapsed Cases
por: WingChing, Li, et al.
Publicado: (2023)

The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
por: Baek, Han-Sang, et al.
Publicado: (2022)

Relapse of Graves' disease with repetitive depression and dysphagia episodes: A case report
por: Sakakura, Koichi
Publicado: (2022)

Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD
por: Jiang, Shenghua, et al.
Publicado: (2018)

Evaluation of IL-17 and IL-35 Serum Levels in Patients with Preeclampsia
por: Batebi, Atefeh, et al.
Publicado: (2019)

IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
por: Chimenz, Roberto, et al.
Publicado: (2022)

Increased Circulating Th17 Cells, Serum IL-17A, and IL-23 in Takayasu Arteritis
por: Misra, Durga Prasanna, et al.
Publicado: (2016)

The association of IL-17A polymorphisms with IL-17A serum levels and risk of ischemic stroke
por: Huang, Hua-Tuo, et al.
Publicado: (2017)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse
por: Lu, Linsong, et al.
Publicado: (2020)

High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma
por: Liao, Rui, et al.
Publicado: (2013)

Continued Elevation of Plasma IL-4 and IL-17 Predicts the Progression from VMC to DCM
por: Wang, Z. H., et al.
Publicado: (2020)

The role of IL-6 and osteoprotegerin in bone metabolism in patients with Graves’ disease
por: OMMA, Tülay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nvu7ibpakr2m66pg1uff9k4aic